Main Menu

Dr Marco Gerlinger

Team Leader

The alt text
Dr Marco Gerlinger developed new tools to detect and track the evolution of cancer cells and of their microenvironment and better therapies which prevent the evolution of drug resistance. He holds an Honorary Consultant Medical Oncologist position at The Royal Marsden NHS Foundation Trust, where he treats patients with gastro-intestinal cancers. Based on the research in his lab, he performed clinical trials of novel immunotherapies that aimed to leverage the immune system to attack cancer cells. Dr Gerlinger left the ICR on January 2022. ORCID 0000-0003-2719-299X


Dr Marco Gerlinger studied Medicine in Munich, Wurzburg, London and Boston. After obtaining his MD from the Institute for Immunology in Munich, he undertook postdoctoral training in cancer immunotherapy at the University of Zurich. He specialized in Internal Medicine and Medical Oncology in Zurich and London.

As a postdoc and subsequently as a clinician scientist at the Cancer Research UK London Research Institute, he investigated biomarkers of targeted cancer drug resistance and developed technologies to measure and track genetic and functional intra tumour heterogeneity and cancer evolution.

Dr Gerlinger joined the ICR's Centre for Evolution and Cancer as a team leader in October 2013. He is also a Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust where he treats patients with gastrointestinal cancers. 

Dr Gerlinger left the ICR on January 2022.

Dr Gerlinger is a member of the Cancer Research UK Convergence Science Centre, which brings together leading researchers in engineering, physical sciences, life sciences and medicine to develop innovative ways to address challenges in cancer.

Convergence Science Centre